Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0
暂无分享,去创建一个
[1] Stephen B. Duffull,et al. Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[2] D. Bates,et al. Mixed-Effects Models in S and S-PLUS , 2001 .
[3] Eric Walter,et al. Identification of Parametric Models: from Experimental Data , 1997 .
[4] N. Holford. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.
[5] L. Petzold. Automatic Selection of Methods for Solving Stiff and Nonstiff Systems of Ordinary Differential Equations , 1983 .
[6] W. J. Studden,et al. Theory Of Optimal Experiments , 1972 .
[7] Goonaseelan Pillai,et al. Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[8] France Mentré,et al. Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.
[9] W. Näther. Optimum experimental designs , 1994 .
[10] P M Aggeler,et al. Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose , 1968, Circulation.
[11] P. Laycock,et al. Optimum Experimental Designs , 1995 .
[12] France Mentré,et al. Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[13] Jon Wakefield,et al. Population modelling in drug development , 1999, Statistical methods in medical research.
[14] France Mentré,et al. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..
[15] R A O'REILLY,et al. STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.
[16] N H Holford,et al. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. , 1986, Clinical pharmacokinetics.
[17] France Mentré,et al. Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[18] Andrew C. Hooker,et al. Software for optimal design in population pharmacokinetics and pharmacodynamics : a comparison , 2007 .
[19] France Mentré,et al. Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates , 2007, Statistics in medicine.
[20] L. Sheiner,et al. Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.
[21] Leon Aarons,et al. Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments , 2008, Journal of biopharmaceutical statistics.
[22] Alain Mallet,et al. Optimal design in random-effects regression models , 1997 .
[23] France Mentré,et al. Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model , 2009, Statistics in medicine.
[24] Malcolm Rowland,et al. Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[25] John A. Nelder,et al. A Simplex Method for Function Minimization , 1965, Comput. J..
[26] Paolo Vicini,et al. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments , 2005, The AAPS Journal.
[27] D. Bates,et al. Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.
[28] France Mentré,et al. Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.
[29] France Mentré,et al. Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics , 2009 .
[30] R. S. Stepleman,et al. Scientific computing : applications of mathematics and computing to the physical sciences , 1983 .